Batch of positive opinions from Europe's Committee for Medicinal Products for Human Use recent meetings

The European Medicines agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has released highlights of its June 21-24 meetings, which included several positive opinions to recommend backing approval of new drugs, as well extensions of indications and generic copies.

The Committee adopted positive opinions recommending the granting of marketing authorizations for the following new medicines:

' Brinavess (vernakalant), from Merck Sharp & Dohme (Merck & Co), intended for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults;